HC Wainwright Has Positive View of CalciMedica Q3 Earnings

CalciMedica Inc. (NASDAQ:CALC) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of CalciMedica in a research note issued on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.37). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.35) EPS.

CALC has been the topic of a number of other reports. Oppenheimer reduced their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

CalciMedica Trading Down 5.6%

NASDAQ:CALC opened at $0.62 on Tuesday. The firm has a market cap of $9.80 million, a price-to-earnings ratio of -0.47 and a beta of 0.85. The company’s 50-day moving average is $0.64 and its two-hundred day moving average is $2.49. CalciMedica has a 12-month low of $0.46 and a 12-month high of $7.20.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter.

Institutional Trading of CalciMedica

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its position in CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares in the last quarter. 180 Wealth Advisors LLC increased its position in CalciMedica by 297.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in CalciMedica during the 4th quarter worth approximately $506,000. Jane Street Group LLC acquired a new stake in CalciMedica during the 4th quarter worth approximately $127,000. Finally, PVG Asset Management Corp acquired a new stake in CalciMedica during the 4th quarter worth approximately $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.